Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 50561 in Patients With Mild or Moderate Alzheimer's Disease

NCT05811442 is registered in ClinicalTrials.gov with Beijing Joekai Biotechnology LLC as lead sponsor.

NCT NCT05811442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05811442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 50561 in Patients With Mild or Moderate Alzheimer's Disease
Lead sponsor
Beijing Joekai Biotechnology LLC
Phase
Phase 2
Overall status
Completed
Start date
April 18, 2023
Completion date
September 11, 2025
Enrollment
68 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease